Trust Company’s Vanda Pharmaceuticals VNDA Stock Holding History

Trust Company’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-250	Closed	-$3K	–	328
2019 Q3	$3K	Buy	+250	New	+$3.48K	﹤0.01%	298

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Trust Company's VNDA Position: Q4 2019 in Review

Trust Company sold out of Vanda Pharmaceuticals (VNDA) in Q4 2019, closing a stake of 250 shares — an estimated $3K sold.

Trust Company first reported a position in VNDA in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 179 funds tracked by Wall St. Rank hold VNDA as of Q4 2019.

Trust Company reported no remaining Vanda Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Trust Company sold 250 Vanda Pharmaceuticals shares in Q4 2019, an estimated $3K.
Trust Company first reported a position in Vanda Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Trust Company's Vanda Pharmaceuticals position peaked at $3K in Q3 2019.
179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2019.

Based on Trust Company's 13F filing for Q4 2019, filed 7 Jan 2020.